Document:

EX-10.40

 Exhibit 10.40 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
 AMENDMENT 5 TO SUB-LICENSE AND
COLLABORATION AGREEMENT 
 This Amendment 5 (the “Amendment”) to the Sub-Licence
and Collaboration Agreement dated March 20, 2012, as amended, (the “2012 Agreement”) is entered into and effective as of the last date of signature (the “Amendment Effective Date”), by and between: 

MedImmune, LLC, having a place of business at One MedImmune Way, Gaithersburg, MD 20878, USA (“MedImmune”); and 

Humabs BioMed SA, a limited company organized and existing under the laws of Switzerland, having its head office at Via Mirasole 1, Bellinzona CH-6500 Switzerland (“Humabs”). 
 MedImmune and Humabs may each be referred to herein individually as a
“Party” and collectively as the “Parties”. 
 Background 

(A) WHEREAS, MedImmune and Humabs entered into the 2012 Agreement (which for clarity incorporates and includes each of its Amendments 1 through
4); 
 (B) WHEREAS, the Parties desire to further amend certain provisions of the 2012 Agreement to clarify the Parties’ intents, remove
certain ambiguities and to align the provisions of the 2012 Agreement with provisions of similar intent in the Exclusive License and Collaboration Agreement between the Parties dated December 31, 2013, as amended (the “2013
Agreement”), 
 Terms and Conditions 

NOW, THEREFORE, in consideration of the mutual covenants contained in this Amendment, and other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, MedImmune and Humabs, intending to be legally bound, hereby agree as follows: 
 1. DEFINITIONS

  

	1.1	 Any capitalised terms not separately defined in this Amendment shall have the meaning ascribed to them in the
2012 Agreement. 

 2. AMENDMENT 
  

	2.1	 Section 1.1.95 shall be amended to read as follows: 

 

	 	1.1.95.	 “Research Project Materials” includes but is not limited to the (a) Flu Products,
(b) Second Target Products, (c) Biologics directed to an Extra Target (where applicable), (d) any other biological, chemical, pharmaceutical or other organic or inorganic materials or devices created, reproduced, modified, treated,
purified, isolated, fractionated 

  

					
		  	Page 1 of 5	  	/s/ FR   /s/DC

	 	or tested in the performance of any Research Project, and (e) all progeny, derivatives, clones, sub-clones, Modifications, improvements (including proteins, antibodies,
functional subunits, vectors, cells, cell lines) and devices to the extent used or useful for the administration, creation, reproduction, modification, treatment, purification, isolation, fractionation or testing of any of the foregoing
(a) through (d) in the performance of any Research Project. For the avoidance of doubt, Research Project Materials does not include or incorporate any materials or devices of an Acquiror as set out in Section 17.4. 

 

	2.2	 Section 2.7 shall be deleted in its entirety and replaced with the following: 

 

	 	2.7	 MedImmune shall have the right to grant sub-licences pursuant to any of
the licences granted to it pursuant to clauses 2.1 and 6.1 to any of its Affiliates or Third Parties through multiple tiers (each such sublicensee shall be deemed a MedImmune Sublicensee). In the event of any sublicense, MedImmune shall remain
primarily responsible for all of its MedImmune Sublicensees’ activities and any and all failures by its MedImmune Sublicensees to comply with the applicable terms of this Agreement. Any sublicense shall be consistent with the terms and
conditions of this Agreement. Promptly following entry of such sublicense agreement, MedImmune will provide a copy of such agreement to Humabs (which may be redacted for sensitive commercial information not relevant to MedImmune’s obligations
hereunder). 

  

	2.3	 Section 12.3 shall be deleted in its entirety and replaced with the following: 

 

	 	12.3	 Indemnification of Humabs. MedImmune shall indemnify, defend and hold harmless Humabs, its Affiliates
and its and their respective directors, officers, agents and employees (“Humabs Indemnitees”) in full, from and against any and all Liabilities incurred by them to the extent resulting from or arising out of any claims made or suits
brought by a Third Party (collectively, “Third Party Claims”) against Humabs, its Affiliates or its or their respective directors, officers, agents or employees that arise or result from (i) the development, manufacture or
commercialization of Licensed Products by or on behalf of MedImmune or its Affiliates or MedImmune Sublicensees, including Third Party Claims based upon product liability and patent infringement, (ii) the breach of any of MedImmune’s
obligations under this Agreement, including MedImmune’s representations, warranties, and covenants set forth herein, or (iii) any intentional misconduct or negligence on the part of MedImmune or its Affiliates or its Sublicensees or the
officers, directors, employees, or agents of MedImmune, its Affiliates or its Sublicensees. The foregoing indemnity obligation shall not apply to the extent (a) such Third Party Claim arises from any activities for which Humabs has an
obligation to Indemnify MedImmune and its Affiliates pursuant to clause 12.4, as to which Liability each Party shall indemnify the other to the extent of their respective liability for such Liability or (b) that the Humabs

  

					
		  	Page 2 of 5	  	/s/ FR   /s/DC

 Indemnitees fail to comply with the indemnification procedures set forth in
Section 12.5 and MedImmune’s defense of the relevant Third Party Claim(s) is prejudiced by such failure. 
  

	2.3	 Section 12.4 shall be deleted in its entirety and replaced with the following: 

 

	 	12.4	 Indemnification of MedImmune. Humabs shall indemnify, defend and hold harmless MedImmune, its
Affiliates, Sublicensees and its and their respective directors, officers and employees (“MedImmune Indemnitees”) in full from and against any and all Liabilities incurred by MedImmune Indemnitees to the extent resulting from or
arising out of any Third Party Claims against MedImmune, its Affiliates, sublicensees or its or their respective directors, officers or employees that arise or result from (1) the breach of any of Humabs’ obligations under this Agreement,
including Humabs’ representations, warranties, and covenants set forth herein, or (ii) any intentional misconduct or negligence on the part of Humabs or its Affiliates or the officers directors, employees or agents of Humabs or its
Affiliates. The foregoing indemnity obligation shall not apply to the extent (a) such Third Party Claim arises from any activities for which MedImmune has an obligation to Indemnify Humabs and its Affiliates pursuant to clause 12.3, as to which
Liability each Party shall indemnify the other to the extent of their respective liability for such Liability, and (b) that the MedImmune Indemnitees fail to comply with the indemnification procedures set forth in Section 12.5 and
Humabs” defense of the relevant Third Party Claim(s) is prejudiced by such failure. 

 12.4.1. [***]. 

  

					
		  	Page 3 of 5	  	/s/ FR   /s/DC

	2.4	 Section 17.4 shall be amended to include the following: 

In the event of any such assignment under this clause 17.4 in connection with a Change of Control of either Party to a Third Party acquirer
(such Third Party acquiror, an “Acquiror”). all Intellectual Property owned or otherwise Controlled by the Acquiror or its Affiliates (except for Humabs or MedImmune, if remaining as a separate Affiliate or otherwise the successor
entity thereto) shall he excluded from all licenses granted under this Agreement (including in each case any such Intellectual Property owned or otherwise Controlled by such Acquirer or its Affiliates as of the date of consummation of such
transaction), except for any intellectual property right generated by the Acquirer or its Affiliates in performing any activity under this Agreement or any Improvement to Licensed Patent or Licensed Know-How
made by Humabs after the date of such Change of Control if remaining as a separate Affiliate or otherwise the successor entity thereto). 
 3. ENTIRE
AGREEMENT 
  

	3.1	 This Amendment, together with the 2012 Agreement and the DARPA Subcontract dated 29 August, 2016,
constitutes the entire agreement between the Parties with respect to the subject matter hereto. The 2012 Agreement, together with this Amendment and the DARPA Subcontract, supersedes all prior agreements, whether written or oral, with respect to the
subject matter of the 2012 Agreement, as amended. Each Party confirms that it is not relying on any representations, warranties or covenants of the other Party except as specifically set out in the 2012 Agreement as amended. Nothing in this
Amendment is intended to limit or exclude any liability for fraud. The Parties hereby agree that subject to the modifications specifically stated in this Amendment, all terms and conditions of the 2012 Agreement shall remain in full force and
effect. 

  

					
		  	Page 4 of 5	  	/s/ FR   /s/DC

 IN WITNESS WHEREOF, THE PARTIES ACKNOWLEDGE AND AGREE THAT THIS AMENDMENT IS MADE AND
ENTERED INTO IN MUTUALLY ACCEPTABLE FORM TO BE EXECUTED AND EFFECTIVE AS OF THE AMENDMENT EFFECTIVE DATE. 
  

					
	Signed:	 	 /s/John Trainer
	 	
	For and on behalf of MedImmune, LLC	 	
			
	Name:	 	 John Trainer
	 	
	Position:	 	VP, P&S	 	
			
	Date:	 	17 July 17	 	
			
	Signed:	 	 /s/Filippo Riva
	 	
	For and on behalf of Humabs BioMed SA	 	
			
	Name:	 	Filippo Riva	 	
	Position:	 	CEO/CFO	 	
			
	Date:	 	July 15th, 2017	 	
			
	Signed:	 	 /s/Davide Corti
	 	
	For and on behalf of Humabs BioMed SA	 	
			
	Name:	 	Davide Corti	 	
	Position:	 	CSO	 	
			
	Date:	 	July 15th, 2017	 	

  

					
		  	Page 5 of 5EX-10.41

 Exhibit 10.41 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
  
 

 
 September 7, 2018 
 Eric
Victory 
 Vice President & Head for Cardiovascular & Metabolic Disease, Partnering & Strategy 

MedImmune, Inc. 
 One MedImmune Way 

Gaithersburg, MD 20878 
 Re: Amendment No. 6 to Sub-Licence and Collaboration Agreement 
 Dear Eric, 

As you know, Humabs Biomed SA (“Humabs”), a wholly owned subsidiary of Vir Biotechnology Inc., and MedImmune, LLC
(“MedImmune”) are parties to that certain Sub-Licence and Collaboration Agreement dated March 20, 2012, as amended (the “Agreement”). By this letter amendment (this
“Amendment”), Humabs and MedImmune agree to amend the Agreement as described below, effective as of the date first set forth above. 

Subclause (i) of Section 2.4 of the Agreement, as amended by Amendment No. 4 to the Sub-Licence and
Collaboration Agreement, is hereby amended and replaced in its entirety to read as follows: 
 [***] 

Clause 9.7.2 of the Agreement is hereby amended and replaced in its entirety to read as follows: 

“A Receiving Party may disclose the existence and terms of this Agreement and the Confidential Information of the Disclosing Party to its
attorneys and advisors and to potential acquirers in connection with a potential consolidation, acquisition, merger or similar transaction and to existing and potential investors or lenders of the Receiving Party, as a part of their due diligence
investigations, and/or to potential licensees and/or to potential collaborators and/or to permitted assignees, in each case under a written agreement to keep 
  

 

  
 1 

 of their due diligence investigations, and/or to potential licensees and/or to potential
collaborators and/or to permitted assignees, in each case under a written agreement to keep the terms of this Agreement confidential and to use the Confidential Information solely for the purpose permitted pursuant to this clause.” 

Any capitalized terms used herein and not otherwise defined herein will have the meaning ascribed in the Agreement. Except as expressly set forth herein, all
of the terms of the Agreement will remain in full force and effect. 
 Please indicate MedImmune’s agreement to the foregoing by having an authorized
representative of Medlmmune sign this Amendment in the appropriate signature line below. 
  

							
		 		 	Agreed and accepted:
			
	Sincerely,	 		 	MedImmune, LLC
				
	 /s/ Filippo Riva
	 	    	 	By:	 	 /s/ JoAnn Suzich

	Filippo Riva	 		 	Name:	 	JoAnn Suzich
	Managing Director	 		 	Title:	 	Vice President, Research
		 		 	Date:	 	07 September 2018

  
 

 

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]